Does the βTG/PF₄ Ratio Have Any Value in Myeloproliferative Diseases?

• References

• 1 Walsh PN, Murphy S, Barry WE. The role of platelets in the pathogenesis of thrombosis and hemorrhage in patients with thrombocytosis. Thromb Haemostas 1977; 38: 1085-1096
• 2 Wu KK. Platelet Hyperaggregability and thrombosis in patients with thrombocythemia. Ann Int Med 1978; 88: 7-11
• 3 Cooper B, Schafer AI, Pucholsky D, Handin RI. Platelet resistance to prostaglandin D₂ in patients with myeloproliferative disorders. Blood 1978; 53: 618-626
• 4 Bougthon BJ, Allington MJ, King A. Platelet and plasma Beta- thromboglobulin in myeloproliferative syndromes and secondary thrombocytosis. Br J Haematol 1978; 40: 125-132
• 5 Cortelazzo S, Viero P, Barbui T. Platelet activation in myeloproliferative disorders. Thromb Haemostas 1981; 45: 211-213
• 6 Ireland H, Lane DA, Wolff S, Foadi M. In vivo platelet release in myeloproliferative disorders. Thromb Haemostas 1982; 48: 41-45
• 7 Kaplan KL, Owen J. Plasma levels of Beta-thromboglobulin and platelet factor 5 as indices of platelet activation in vivo. Blood 1980; 57: 199-202
• 8 Dawes J, Smith RC, Pepper DS. The release, distribution and clearance of human beta-thromboglobulin and platelet factor 4. Thromb Res 1978; 12: 851-866